Global Leaders Seek to Eliminate Pediatric HIV by 2030

June 15, 2021 by Alexa Hornbeck
Global Leaders Seek to Eliminate Pediatric HIV by 2030

The COVID-19 pandemic has disrupted routine health services making it difficult to deliver high-quality care to pregnant women and children living with HIV. But it has also pushed global leaders to try and reinvigorate global commitments to eliminate pediatric HIV by 2030.

“Children living with HIV face a stark reality, they make up 4% of all people living with HIV, and they make up 14% of the deaths, and that’s because treatment coverage is abysmal,” said Shannon Hader, deputy executive director of UNAIDS and assistant secretary-general of the United Nations.

HIV, known as the human immunodeficiency virus, attacks the immune system and is often transmitted through contact with infected blood, semen, or vaginal fluids. In the case of children, HIV is often transmitted to an infant through pregnancy or breastfeeding, and in many cases, is left untreated or diagnosed until the child is older. 

Currently, there are over 850,000 children living with HIV who are not in care and treatment, according to the United Nations. 

“At a local level, you have to think about where do we find these kids, what’s different than dealing with infant clinics, and how do you incentivize it,” Hader said.

Last week, the United Nations adopted a set of new and ambitious targets in a political declaration at the United Nations General Assembly High-Level Meeting on AIDS, to prevent 3.6 million new HIV-infections and 1.7 million AIDS-related deaths by 2030.

To formulate a plan, the Center for Strategic and International Studies Global Health Policy Center brought together experts from the Pediatric AIDS Foundation, ViiV Healthcare, PEPFAR, UNAIDS, Elizabeth Glaser Pediatric AIDS Foundation, and the Global Fund.

“This year was the most inclusive strategy process ever, we had inputs from over 10,000 stakeholders in 160 countries,” Hader said.

Since early spring, these agencies have undergone multiple efforts to change the approach to pediatric HIV treatment, development, and research, with the UNAIDS board approving a new strategy to combat inequities and the Global Fund developing a new strategy to be finalized and approved later this year.

There was the launch of the global accelerator for pediatric formulations network, housed in the World Health Organization, called GAP-f, which was conceived to build on and formalize the model developed within the HIV community to provide a sustainable mechanism that ensures that safer, more effective, and more durable pediatric formulations are developed and made available to children against an accelerated timeline.

The Vatican took steps to try to accelerate working with regulators, drug companies, and other stakeholders like UNICEF and the World Health Organization, on the development and uptake of HIV and TB diagnostics and medicines for children, known as the Rome Action Plan.

“We’ve got a political declaration that sets the tone for the next five years, we’ve got a strategy characterized and approved by UNAIDS with an enormous amount of input, but the shift that has to occur at the national level is a political determination to get it done,” said Charles J. Lyons, president and chief executive officer of the Elizabeth Glaser Pediatric AIDS Foundation. 

COVID-19 played a role in both dismantling the work being done to combat HIV among youth and strengthening the need for policy efforts to address the gaps in kids who are diagnosed with HIV who are not getting treatment.

“Perhaps we can get more interest, when we put these pandemics together, to not just procuring, but to actually committing to the maintenance of point of care diagnostics and viral diagnostics at the scale and resourcefulness that we need them at,” Hader said.

Still, she said that to achieve the goal of eliminating pediatric HIV, there would need to be better detection of the kids with HIV who aren’t currently captured in data.

“If we don’t want to do this every year, we still need to find every single positive kid who’s being born, who is an infant. And right now, we only have 60% coverage of early infant diagnosis at two months, so we’re still missing 40% of the exposed kids,” said Hader.

Hader said PEPFAR, the President’s Emergency Plan for AIDS Relief, has been trying to locate these children through focused strategies like finding them through parents and by use of an index test which helps identify if their child has developed HIV through transmission. 

“We have to talk to the parents and find out, what would it take for you to want to know your kid is positive, of course everybody wants their kid to be healthy… but do you really want to open up a box that has something that might scare you, unless there is the support around to take that on,” said Hader.

Hader said that another important strategy might be to lower the age of consent for older adolescents to be able to get self-testing or go to the clinic on their own to fill in the missing gaps, and that services should be also differentiated to avoid common discriminatory care practices. 

“We know there are a certain amount of remaining infections from women getting newly infected during pregnancy or breastfeeding. Who are those women, and how are we reaching them more intensively in a preventive manner?” asked Hader.

To answer that, PEPFAR has been working to integrate women’s health services into family planning and maternal and child health service delivery sites and utilizing service delivery sites as entry points for vulnerable subpopulations including adolescent girls and young women.

PEPFAR is also working to prevent mother-to-child transmission for pregnant and breastfeeding women through enhanced access to PrEP, also known as pre-exposure prophylaxis, which is a medicine that those who are at risk of HIV often take to prevent getting HIV from sex or injection drug use. 

Last year in June, the U.S. The Food and Drug Administration approved a drug called dolutegravir, referred to as pediatric DTG, for treating children down to four weeks of age who have HIV, and the regimen has become the superior treatment when compared to others on the market like Lopinavir or Ritonavir.

“We have been constantly working with our partners to push country teams to transition all children to pediatric DTG, as quickly as possible, irrespective of the amount of Lopinavir or Ritonavir that countries have in stock. It’s just not acceptable to have a superior regimen, and not push in the direction to get kids there,” said Angeli Achrekar, acting U.S. Global AIDS coordinator and special representative for Global Health Diplomacy in the U.S. State Department.. 

Currently four countries have already received their first shipment of pediatric DTG, and there are 19 countries that will receive their pediatric DTG by the end of this year.

“It’s been a great week… but I think we still have a long way to go to flip the script, and maybe look at our global framework as supporting what we need for political will and political action on the ground, at the country and regional level,” Hader said.

A+
a-
  • health
  • HIV
  • Pediatric HIV
  • UNAIDS
  • In The News

    Health

    Voting

    Health

    Biden Announcing New Rule to Protect Consumers Who Purchase Short-Term Health Insurance Plans

    President Joe Biden on Thursday announced new steps to protect consumers who buy short-term health insurance plans that critics say amount to junk. A... Read More

    President Joe Biden on Thursday announced new steps to protect consumers who buy short-term health insurance plans that critics say amount to junk. A new rule finalized by the Democratic president's administration will limit these plans to just three months. And the plans can only be renewed for a maximum... Read More

    March 27, 2024
    by Dan McCue
    One-Time Treatment Could Revitalize Immune Systems in the Elderly

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of... Read More

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of immune cell could potentially revitalize the immune systems of the elderly, helping their bodies better react to viral and bacterial threats. The research was carried out... Read More

    March 27, 2024
    by Dan McCue
    Insurers to Expand Access to ‘Navigation Services’ for Cancer Patients

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients... Read More

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients and their families navigate the myriad challenges that might arise during treatment for cancer and other serious illnesses. The insurers involved are Aetna; Blue Cross Blue... Read More

    Five Takeaways From the Abortion Pill Case Before US Supreme Court

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone,... Read More

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone, in a case that could have far-reaching implications for millions of American women and for scores of drugs regulated by the Food and Drug Administration. It's... Read More

    Biden and Harris Argue Democrats Will Preserve Health Care and Republicans Would Take It Away

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in... Read More

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in the battleground state of North Carolina, arguing that Democrats like themselves would preserve access to care while Republicans would reverse gains made over the past decade... Read More

    March 26, 2024
    by Tom Ramstack
    Supreme Court Skeptical of Ban on Abortion Pill Mifepristone

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access... Read More

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access to the abortion pill mifepristone despite objections from anti-abortion activists. The doctors and organizations who sued argued the Food and Drug Administration was wrong in granting... Read More

    News From The Well
    scroll top